Clinical Trial Search

Primary: The Number of Participants With Lower Gastrointestinal Acute Graft-Versus-Host-Disease Treatment Response Rate on Day 28 — 19; 8 Participants

Primary: 1-year Event Free Survival (EFS) — 12; 24 percentage of participants — p=< 0.05

Primary: Clinical Improvement Rate (Number of Subjects Showing Clinical Improvement/Number of Subjects Evaluated x 100) — 31.4; 24.1; 44.4; 30.0 percentage of participants

Primary: Response Signature in Transfusion Dependent MDS Patients — 24; 1; 17; 6 Participants

Primary: 4M PFS Rate of Patients With Previously Untreated, Unresectable Malignant Pleural Mesothelioma (MPM) Treated With CBP501, Pemetrexed and Cisplatin — 25; 9; 27; 13…

Primary: Overall Response Rate — 2.4 months

Primary: Number of Participants With Favorable Clinical Response at End of Inpatient Intravenous Therapy (EOIV) — 41; 36 Participants

Primary: Number of Participants With Acute Cellular Rejection Between Study and Control Groups — 1; 1 Participants

Primary: Percent Change From Baseline in Psoriasis Assessment of Severity Index (PASI) at Week 12 — -28.043; -37.361 percentage change — p=0.8495

Primary: Ammonia Plasma Levels at Baseline and Day 5 — 70.4; 91.4; 92.6; 78.1 μmol/L

Primary: Change From Baseline to Week 12 in Disease Activity Score (DAS) 28 (C-reactive Protein [CRP]) — -2.51; -2.65 score on a scale — p=0.022

Primary: Primary Endpoint Clinician-Administered PTSD Scale for DSM-5 (CAPS-5) Total Severity Score — 16.3 score on a scale

Primary: Percentage of Subjects With Confirmed Keloid Formation at Treated vs. Untreated Lesions at 24 Weeks — 92.9; 85.7 percentage of participants

Primary: Number of Participants With AEs and Abnormal Lab Values, Vital Signs, and PE Findings — 11; 13; 4; 4 subjects

Primary: Change in Alzheimer Disease Assessment Scale-cognitive (ADAS-cog) Score at Week 12 Visit Compared to Baseline — -0.05; -2.25 score on a scale